Section Arrow
Quote
SION.NASDAQ
- Sionna Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/21 06:05 EDT
Pre Market
Last
 --
-- (--)
Bid
6.7
Ask
26.61
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 16.74
-1.59 (-8.67%)
Day High 
19.198 
Prev. Close
18.33 
1-M High
21.94 
Volume 
395.73K 
Bid
6.7
Ask
26.61
Day Low
16.59 
Open
18.64 
1-M Low
13.81 
Market Cap 
808.21M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 20.13 
20-SMA 18.13 
50-SMA 15.8 
52-W High 25.19 
52-W Low 7.255 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.50/-2.69
Enterprise Value
816.89M
Balance Sheet
Book Value Per Share
7.98
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.79 -0.285 -2.02%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.048 +0.0003 +0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.17 +0.33 +5.65%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.05 +0.13 +2.20%
Quotes are at least 15-min delayed：2025/07/21 06:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.